Amicus Therapeutics (FOLD) Short Interest Ratio & Short Volume → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free FOLD Stock Alerts $9.80 -0.08 (-0.81%) (As of 05/31/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Amicus Therapeutics Short Interest DataCurrent Short Interest28,910,000 sharesPrevious Short Interest28,770,000 sharesChange Vs. Previous Month+0.49%Dollar Volume Sold Short$279.27 millionShort Interest Ratio9.5 Days to CoverLast Record DateMay 15, 2024Outstanding Shares296,199,000 sharesPercentage of Shares Shorted9.76%Today's Trading Volume2,904,632 sharesAverage Trading Volume2,462,047 sharesToday's Volume Vs. Average118% Short Selling Amicus Therapeutics ? Sign up to receive the latest short interest report for Amicus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartFOLD Short Interest Over TimeFOLD Days to Cover Over TimeFOLD Percentage of Float Shorted Over Time Ad Wealthpin ProAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. Amicus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202428,910,000 shares $279.27 million +0.5%N/A9.5 $9.66 4/30/202428,770,000 shares $287.41 million -8.1%N/A9.4 $9.99 4/15/202431,320,000 shares $333.87 million -3.6%N/A10.3 $10.66 3/31/202432,490,000 shares $382.73 million +0.3%N/A10.7 $11.78 3/15/202432,400,000 shares $371.95 million +4.8%N/A10.3 $11.48 2/29/202430,910,000 shares $396.27 million +15.4%N/A9.4 $12.82 Get the Latest News and Ratings for FOLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202426,780,000 shares $374.92 million +9.8%N/A8.6 $14.00 1/31/202424,400,000 shares $303.29 million -2.6%N/A8.1 $12.43 1/15/202425,060,000 shares $330.29 million -2.7%N/A8.3 $13.18 12/31/202325,750,000 shares $365.39 million -4.3%N/A8.8 $14.19 12/15/202326,910,000 shares $342.30 million +11.5%N/A9.2 $12.72 11/30/202324,140,000 shares $266.02 million +6.2%N/A9.6 $11.02 11/15/202322,730,000 shares $242.30 million +0.8%N/A9.6 $10.66 10/31/202322,560,000 shares $247.48 million +0.4%N/A10 $10.97 10/15/202322,480,000 shares $234.69 million +19.1%N/A9.3 $10.44 9/30/202318,870,000 shares $229.46 million -0.2%N/A7.9 $12.16 9/15/202318,900,000 shares $247.40 million -3.8%N/A8.6 $13.09 8/31/202319,640,000 shares $251.78 million +3.1%N/A8.5 $12.82 8/15/202319,050,000 shares $247.46 million -16.6%N/A7.9 $12.99 7/31/202322,830,000 shares $310.94 million +13.3%N/A8.2 $13.62 7/15/202320,150,000 shares $270.01 million -6.5%N/A7.9 $13.40 6/30/202321,540,000 shares $270.54 million +10.0%N/A8.7 $12.56 6/15/202319,580,000 shares $253.76 million +2.4%N/A7.6 $12.96 5/31/202319,120,000 shares $215.29 million -10.2%N/A7.6 $11.26 5/15/202321,300,000 shares $238.56 million -1.1%N/A8.7 $11.20 4/30/202321,530,000 shares $248.46 million +2.2%N/A9.8 $11.54 4/15/202321,060,000 shares $240.08 million +5.4%N/A9.9 $11.40 3/31/202319,980,000 shares $221.58 million -4.3%N/A8.9 $11.09 3/15/202320,880,000 shares $238.66 million +15.4%N/A9.8 $11.43 2/28/202318,090,000 shares $238.61 million +0.2%N/A8.6 $13.19 2/15/202318,060,000 shares $236.77 million -8.1%N/A8.8 $13.11 1/31/202319,650,000 shares $256.24 million +1.5%N/A9.3 $13.04 1/15/202319,370,000 shares $248.52 million -3.8%N/A8.5 $12.83 12/30/202220,140,000 shares $245.91 million +12.6%N/A9.2 $12.21 12/15/202217,880,000 shares $216.17 million -12.0%N/A7.8 $12.09 11/30/202220,310,000 shares $245.75 million +7.6%N/A8.3 $12.10 11/15/202218,880,000 shares $220.33 million +3.4%N/A7.4 $11.67 10/31/202218,260,000 shares $182.60 million -12.1%N/A7.1 $10.00 10/15/202220,780,000 shares $220.27 million +2.3%N/A7.8 $10.60 9/30/202220,310,000 shares $212.04 million -8.5%N/A7.3 $10.44Are You Positioned For The New Energy Goldrush? (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. 9/15/202222,200,000 shares $243.09 million +2.5%N/A7.4 $10.95 8/31/202221,660,000 shares $243.24 million +13.2%N/A6.9 $11.23 8/15/202219,130,000 shares $236.64 million -5.2%N/A5.8 $12.37 7/31/202220,170,000 shares $200.89 million -7.3%N/A5.4 $9.96 7/15/202221,750,000 shares $235.99 million -18.5%N/A5.6 $10.85 6/30/202226,700,000 shares $286.76 million -10.8%N/A7 $10.74 6/15/202229,930,000 shares $245.13 million -4.2%N/A7.5 $8.19 5/31/202231,240,000 shares $238.05 million +8.2%N/A8.2 $7.62 5/15/202228,880,000 shares $216.31 million +6.3%N/A7.7 $7.49 4/30/202227,170,000 shares $192.36 million -3.3%N/A8 $7.08 4/15/202228,090,000 shares $230.06 million +1.3%N/A9.4 $8.19 3/31/202227,720,000 shares $262.51 million -1.8%N/A8.6 $9.47 3/15/202228,220,000 shares $252.57 million +2.7%N/A9.7 $8.95 2/28/202227,490,000 shares $223.77 million +3.0%N/A10.1 $8.14 2/15/202226,680,000 shares $255.06 million +3.7%N/A10.5 $9.56 1/31/202225,720,000 shares $242.03 million +6.8%N/A10 $9.41 1/15/202224,080,000 shares $253.56 million -7.6%N/A9.6 $10.53 12/31/202126,070,000 shares $301.11 million +4.0%N/A10.8 $11.55 12/15/202125,060,000 shares $266.89 million -0.1%N/A10.1 $10.65 11/30/202125,080,000 shares $268.61 million +2.8%N/A10.2 $10.71 11/15/202124,390,000 shares $280.73 million -15.8%N/A10 $11.51 10/29/202128,970,000 shares $304.19 million -2.4%11.1%12.5 $10.50 10/15/202129,670,000 shares $328.74 million +5.4%11.3%12.7 $11.08 9/30/202128,140,000 shares $268.74 million +4.7%10.8%11.6 $9.55 9/15/202126,880,000 shares $299.44 million -2.2%10.3%12.8 $11.14 8/31/202127,490,000 shares $313.11 million -1.5%10.5%13.2 $11.39 8/13/202127,910,000 shares $292.50 million -3.6%10.7%12 $10.48 7/30/202128,960,000 shares $269.04 million -2.4%11.1%11.9 $9.29 7/15/202129,660,000 shares $270.80 million -1.0%11.4%12.3 $9.13 6/30/202129,970,000 shares $288.91 million +5.0%11.5%12.3 $9.64 6/15/202128,550,000 shares $295.49 million -6.7%10.9%10.9 $10.35 5/28/202130,600,000 shares $283.36 million -4.9%11.7%11.3 $9.26 5/14/202132,180,000 shares $301.53 million +8.1%N/A10.4 $9.37 4/30/202129,760,000 shares $296.71 million -7.2%N/A7.5 $9.97 4/15/202132,050,000 shares $319.86 million -3.3%N/A7.9 $9.98 3/31/202133,150,000 shares $311.28 million +3.7%N/A8.1 $9.39 3/15/202131,960,000 shares $344.53 million -0.3%N/A8 $10.78 2/26/202132,060,000 shares $382.16 million +3.1%N/A8.1 $11.92 2/12/202131,100,000 shares $582.50 million -2.0%N/A8.6 $18.73 1/29/202131,720,000 shares $612.20 million +16.4%N/A12.3 $19.30 1/15/202127,250,000 shares $634.65 million -8.2%N/A10.9 $23.29 12/31/202029,690,000 shares $681.09 million -10.4%N/A12.5 $22.94 12/15/202033,120,000 shares $790.91 million +13.3%N/A14.2 $23.88 11/30/202029,240,000 shares $679.54 million -3.7%N/A13.3 $23.24 11/15/202030,360,000 shares $667.31 million +4.0%N/A15.3 $21.98 10/30/202029,200,000 shares $535.82 million -0.7%N/A15.2 $18.35 10/15/202029,390,000 shares $482.00 million -1.5%11.6%15.6 $16.40 9/30/202029,830,000 shares $421.20 million -1.3%11.8%15 $14.12 9/15/202030,230,000 shares $420.50 million -0.9%11.9%14.4 $13.91 8/31/202030,490,000 shares $445.15 million -0.1%12.0%12.4 $14.60Are You Positioned For The New Energy Goldrush? (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. 8/14/202030,530,000 shares $439.63 million -1.7%12.0%11.3 $14.40 7/31/202031,070,000 shares $448.96 million -2.8%12.3%10.5 $14.45 7/15/202031,960,000 shares $480.68 million -3.4%12.7%10.4 $15.04 6/30/202033,070,000 shares $513.91 million +3.7%13.1%10.7 $15.54 6/15/202031,900,000 shares $348.67 million -1.2%12.7%9.8 $10.93 5/29/202032,280,000 shares $402.69 million -0.1%12.8%9.6 $12.48 5/15/202032,310,000 shares $359.93 million -5.5%12.8%9.3 $11.14 4/30/202034,200,000 shares $419.29 million -3.9%13.6%10.1 $12.26 4/15/202035,570,000 shares $356.77 million +0.3%14.2%10.2 $10.03 3/31/202035,450,000 shares $454.47 million -2.0%14.1%10 $12.82 3/13/202036,154,700 shares $376.37 million -2.6%14.4%10.6 $10.41 2/28/202037,110,000 shares $322.86 million +1.8%14.8%11.2 $8.70 2/14/202036,460,000 shares $326.68 million -3.8%14.7%11.4 $8.96 1/31/202037,900,000 shares $373.32 million +5.4%15.3%11.6 $9.85 1/15/202035,950,000 shares $385.38 million +8.1%14.5%11.5 $10.72 12/31/201933,260,000 shares $297.34 million +4.8%13.4%10.8 $8.94 FOLD Short Interest - Frequently Asked Questions What is Amicus Therapeutics' current short interest? Short interest is the volume of Amicus Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 28,910,000 shares of FOLD short. Learn More on Amicus Therapeutics' current short interest. What is a good short interest ratio for Amicus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FOLD shares currently have a short interest ratio of 10.0. Learn More on Amicus Therapeutics's short interest ratio. Which institutional investors are shorting Amicus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Amicus Therapeutics: Walleye Trading LLC, and Torno Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Amicus Therapeutics' short interest increasing or decreasing? Amicus Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 28,910,000 shares, an increase of 0.5% from the previous total of 28,770,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Amicus Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Amicus Therapeutics: Arrowhead Pharmaceuticals, Inc. (7.52%), Biohaven Ltd. (10.47%), Bausch Health Companies Inc. (5.17%), Perrigo Company plc (3.08%), BridgeBio Pharma, Inc. (11.26%), Allakos Inc. (5.74%), Blueprint Medicines Co. (7.22%), Exact Sciences Co. (4.61%), Repligen Co. (8.38%), Exelixis, Inc. (3.77%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Amicus Therapeutics stock? Short selling FOLD is an investing strategy that aims to generate trading profit from Amicus Therapeutics as its price is falling. FOLD shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Amicus Therapeutics? A short squeeze for Amicus Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FOLD, which in turn drives the price of the stock up even further. How often is Amicus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FOLD, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Arrowhead Pharmaceuticals Short Interest Biohaven Short Interest Bausch Health Companies Short Interest Perrigo Short Interest BridgeBio Pharma Short Interest Allakos Short Interest Blueprint Medicines Short Interest Exact Sciences Short Interest Repligen Short Interest Exelixis Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FOLD) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.